Cardiology Pharmaceuticals

Zilebesiran’s Long-Lasting Antihypertensive Potential

Zilebesiran

Could the first long-lasting antihypertensive medication be on the way? Results of a Phase 1 study in NEJM suggests that Alnylam Pharmaceuticals’ zilebesiran is a frontrunner to become that drug, showing that a single injection controls blood pressure for up to six months.

Zilebesiran is an investigational RNA interference therapeutic agent that inhibits hepatic angiotensinogen synthesis, which plays a key role in the development of hypertension. 

  • That’s how zilebesiran works, but most news headlines and social media comments focused on how long it works, noting the BP control challenges created by poor adherence to daily antihypertensive pill regimens.

The Phase 1 study included 107 adults with hypertension and was performed in three parts, evaluating zilebesiran at different doses, with specific salt intake diets, and when combined with other hypertensives.

  • Zilebesiran use was associated with dose-dependent serum angiotensinogen level reductions that sustained over six months
  • A ≥200 mg dose of zilebesiran reduced systolic (>10 mm Hg) and diastolic (>5 mm Hg) blood pressure by week 8, which was consistent during day and night, and sustained over six months
  • A 800 mg dose of zilebesiran drove the greatest average systolic and diastolic BP reductions (22.5 mm HG & 10.8 mm HG) at month 6
  • Zilebesiran’s BP reductions were diminished among participants with high salt diets
  • BP reductions were greater when zilebesiran was combined with the BP drug irbesartan 

Adverse events were less common in the zilebesiran group than placebo (72% vs. 88%), most of which were mild or moderate, and there were no reports of hypotension, hyperkalemia, or worsening of renal function.

Although the study was short and small, and some aspects of zilebesiran’s efficacy and safety aren’t confirmed, the authors found these antihypertensive results to be strong enough to justify further research. 

Zilebesiran’s impact might also go beyond BP control, as the associated NEJM editorial suggested that it could also be able to treat other conditions related to renin-angiotensin activation such as kidney and heart disease.

The Takeaway

Although zilebesiran has a lot more to prove, these initial results are promising. And the adherence benefits of a long-lasting antihypertensive drug seems even more promising, once one is developed and approved.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!